NEUMORA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Gain
NEUMORA THERAPEUTICS, INC. (NMRA) reported Debt Securities, Available-for-sale, Unrealized Gain of $9.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2026-03-30
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-09-30 was $9.00K, a 92.04% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-06-30 was -$7.00K.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain for the quarter ending 2025-03-31 was $7.00K, a 22.22% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain for the quarter ending 2024-12-31 was -$44.00K, a 320.00% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain for fiscal 2024 was $70.00K, a 169.23% increase from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain for fiscal 2023 was $26.00K, a 2500.00% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain for fiscal 2022 was $1.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month | Debt Securities, Available-for-sale, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2025-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.00K derived: sum of 2 quarters · filed 2025-11-06 | $9.00K 10-Q · filed 2025-11-06 | -$35.00K derived: sum of 4 quarters · filed 2026-03-30 |
| 2025-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | -$44.00K derived: sum of 3 quarters · filed 2026-03-30 | $69.00K derived: sum of 4 quarters · filed 2026-03-30 |
| 2025-03-31 | $7.00K 10-Q · filed 2025-05-12 | -$37.00K derived: sum of 2 quarters · filed 2026-03-30 | $76.00K derived: sum of 3 quarters · filed 2026-03-30 | $68.00K derived: sum of 4 quarters · filed 2026-03-30 |
| 2024-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $69.00K derived: sum of 2 quarters · filed 2026-03-30 | $61.00K derived: sum of 3 quarters · filed 2026-03-30 | $70.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $105.00K derived: sum of 2 quarters · filed 2024-11-12 | $114.00K 10-Q · filed 2024-11-12 | $134.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2024-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.00K 10-Q · filed 2024-08-06 | $21.00K derived: sum of 3 quarters · filed 2025-03-03 | |
| 2024-03-31 | $9.00K 10-Q · filed 2024-05-07 | $29.00K derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2023-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $26.00K 10-K · filed 2025-03-03 | ||
| 2023-09-30 | $6.00K 10-Q · filed 2023-11-01 | |||
| 2022-12-31 | $1.00K 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |